terutroban terutroban terutroban is an antiplatelet agent developed by servier laboratories. it is a selective thromboxane prostanoid (tp) antagonist and is an orally active drug in clinical development for the secondary prevention of acute thrombotic complications. terutrobanclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status investigational pharmacokinetic dataelimination half-life6–10 hoursidentifiers iupac name 3-((6r)-6--2-methyl-5,6,7,8-tetrahydronaphthalen-1-yl]propanoic acid cas number165538-40-9 n 609340-89-8 (sodium salt)pubchem cid9938840chemspider8114465 nuniia6wx9391d8echa infocard100.107.361 chemical and physical dataformulac20h22clno4smolar mass407.91 g·mol−13d model (jsmol)interactive image smiles cc1=c(c2=c(cc(cc2)ns(=o)(=o)c3=cc=c(c=c3)cl)c=c1)ccc(=o)o inchi inchi=1s/c20h22clno4s/c1-13-2-3-14-12-16(6-9-19(14)18(13)10-11-20(23)24)22-27(25,26)17-7-4-15(21)5-8-17/h2-5,7-8,16,22h,6,9-12h2,1h3,(h,23,24)/t16-/m1/s1 nkey:hweoxfsbsqiwsy-mrxnpfedsa-n n ny (what is this?) (verify) it has been tested in the phase iii clinical trial perform (prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack). the study was prematurely stopped and it could not be determined whether terutroban has a better effect than aspirin. the 2011 clinical trial that studied the antiplatelet agent versus aspirin found that it was not superior in the prevention of cerebral and cardiovascular ischaemic events, although it was significantly better in patients who already suffered previous stroke to the qualifying event. researchers from the university of milan also found in a new research that terutroban can prevent the development of aorta hyperplasia and has beneficial effects on fibrotic processes, leading to the conclusion that it has beneficial effects in preventing or retarding atherogenesis. method of action aside from its anti-inflammatory effect, terutroban is a selective antagonist of the thromboxane receptor. it blocks thromboxane induced platelet aggregation and vasoconstriction.